Edition:
United States

Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
8 Dec 2017
Change (% chg)

$-0.09 (-6.12%)
Prev Close
$1.47
Open
$1.46
Day's High
$1.64
Day's Low
$1.38
Volume
27,332
Avg. Vol
30,251
52-wk High
$10.18
52-wk Low
$1.26

Chart for

About

Achieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage pharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies,... (more)
No analyst recommendations are available for .

Overall

Beta: 1.82
Market Cap(Mil.): $16.49
Shares Outstanding(Mil.): 11.95
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Achieve qtrly loss per share $0.90‍​

* Achieve Life Sciences Inc qtrly loss per share $0.90‍​ Source text for Eikon: Further company coverage:

Nov 09 2017

BRIEF-Achieve Life Sciences entered into exclusive supply agreement with Sopharma AD

* Achieve Life Sciences -‍ co entered into exclusive supply agreement with Sopharma AD for manufacture of Cytisine API and finished tablets​

Oct 26 2017

BRIEF-ACHIEVE LIFE SCIENCES COMMENCES ADVANCEMENT OF CYTISINE CLINICAL DEVELOPMENT PROGRAM

* ACHIEVE LIFE SCIENCES INC - ANNOUNCES COMMENCEMENT OF A MULTI-DOSE STUDY TO EVALUATE BOTH PK AND PD CHARACTERISTICS OF CYTISINE

Oct 04 2017

BRIEF-Achieve announces share purchase agreement with Lincoln Park Capital Fund

* Achieve announces share purchase agreement with Lincoln Park Capital Fund LLC

Sep 14 2017

BRIEF-Achieve Life Sciences ‍announces initiation of Cytisine clinical development program​

* Achieve Life Sciences Inc - ‍Announced initiation of Cytisine clinical development program​

Aug 16 2017

BRIEF-Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences as of Aug 1

* Robert Schacter reports a 16.7 percent passive stake in Achieve Life Sciences Inc as of August 1, 2017 - SEC filing‍​ Source text for Eikon: Further company coverage:

Aug 11 2017

BRIEF-FDA accepts Achieve's IND for its smoking cessation drug

* Achieve announces FDA acceptance of the investigational new drug application (IND) for cytisine as a smoking cessation treatment

Aug 10 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $140.59 +0.58
Novartis AG (NOVN.S) CHF83.10 +1.05
Pfizer Inc. (PFE.N) $35.74 +0.24
Roche Holding Ltd. (ROG.S) CHF240.50 -1.80
Roche Holding Ltd. (RO.S) CHF242.50 -1.40
Merck & Co., Inc. (MRK.N) $55.57 +0.80
Bayer AG (BAYGn.DE) €104.70 +0.55
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €73.18 -0.03
Eli Lilly and Co (LLY.N) $86.45 +0.58

Earnings vs. Estimates